The study of the role of Purified anti-mouse CD193 (CCR3) Antibody in allergic rhinitis mouse animal models

Abstract

Abstract The pathogenesis of allergic asthma is similar to that of allergic rhinitis, with inflammation cells producing and releasing inflammatory mediators and cytokines closely related to CCR3. Related literature has reported that the use of CCR3 monoclonal antibodies can improve symptoms such as allergic enteritis and allergic pneumonitis. Based on the theory of "one airway, one disease", the use of CCR3 monoclonal antibodies may also have a similar effect on allergic rhinitis. However, there are currently few research reports on the application of CCR3 monoclonal antibodies in allergic rhinitis. Therefore, this study aims to explore the effective concentration of CCR3 monoclonal antibodies and compare the effects of different dosing methods, as well as detecting the lung condition of allergic mice to investigate whether antibody treatment can protect the lungs. On the basis of successfully constructing a mouse model of allergic rhinitis, this study uses intraperitoneal injection of three different doses of CCR3 mAb (5uL/mg, 10uL/mg, and 20uL/mg) to observe its therapeutic effects: observing changes in tissue morphology of nasal mucosa, infiltration of inflammation, and using ELISA to detect changes in relevant inflammatory mediators and cytokines, studying the role of CCR3 mAb in inhibiting CCR3-related actions on the nasal mucosa of allergic rhinitis mice. Furthermore, based on the effective concentration, two dosing methods were compared: intraperitoneal injection and topical administration to study the therapeutic effects of both dosing methods.